1. Inicio
  2. Publicaciones
  3. Improved prognosis of young patients with breast cancer undergoing breast-conserving surgery

Improved prognosis of young patients with breast cancer undergoing breast-conserving surgery

Fecha de publicación:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Botteri, E
  • Veronesi, P
  • Rotmensz, N
  • Galimberti, V
  • Thomazini, MV
  • Viale, G
  • Orecchia, R
  • Goldhirsch, A
  • Gentilini, O

Abstract

BackgroundThe aim of the present study was to evaluate how breast cancer prognosis has evolved over time in young women treated with breast-conserving surgery (BCS). MethodsData from patients younger than 40years who had BCS and whole-breast radiotherapy in a single cancer centre between 1997 and 2010 were analysed. The patients were followed until 2016. Endpoints were local recurrence, any breast cancer-related event and death from any cause. ResultsA total of 1331 patients were included in the study. After a median follow-up of 9<bold></bold>3years, 114 local recurrences, 289 breast cancer-related events and 138 deaths had occurred. Women were divided into three groups of similar size based on tertiles of the date of diagnosis: 1997-2002 (524 patients), 2003-2005 (350) and 2006-2010 (457). The risk of local recurrence was 1<bold></bold>42 per 100 person-years in women diagnosed in the first interval, 0<bold></bold>85 per 100 person-years in the second and 0<bold></bold>48 per 100 person-years in the third (P for trend=0<bold></bold>028). The respective values were 3<bold></bold>01, 2<bold></bold>52 and 2<bold></bold>07 per 100 person-years for any breast cancer-related event (P=0<bold></bold>004), and 1<bold></bold>59, 1<bold></bold>22 and 0<bold></bold>64 per 100 person-years for death (P=0<bold></bold>003). Each passing year was associated with a decreasing risk of local recurrence (hazard ratio (HR) 0<bold></bold>93, 95 per cent c.i. 0<bold></bold>87 to 1<bold></bold>00), any breast cancer-related event (HR 0<bold></bold>94, 0<bold></bold>91 to 0<bold></bold>98) and death (HR 0<bold></bold>89, 0<bold></bold>83 to 0<bold></bold>94). A major improvement in prognosis was observed after 2005, when the classification of breast cancer molecular subtypes and use of trastuzumab were implemented in routine clinical practice. ConclusionIn the past two decades, both local control and overall prognosis have improved significantly in young women (aged less than 40years) with breast cancer who undergo BCS. Molecular subtype matters most

Datos de la publicación

ISSN/ISSNe:
0007-1323, 1365-2168

BRITISH JOURNAL OF SURGERY  WILEY

Tipo:
Article
Páginas:
1802-1810
PubMed:
28791694
Factor de Impacto:
2,654 SCImago ℠
Cuartil:
Q1 SCImago ℠

Citas Recibidas en Web of Science: 10

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Campos de Estudio

Proyectos y Estudios Clínicos

A STUDY OF TAK-659 IN COMBINATION WITH NIVOLUMAB IN PARTICIPANTS WITH ADVANCED SOLID TUMORS.

Investigador Principal: ANA SANTABALLA BERTRÁN

C34003 . 2017

SEGURIDAD Y EFICACIA DE ABICIPAR PEGOL (AGN-150998) EN PACIENTES CON DEGENERACIÓN MACULAR NEOVASCULAR ASOCIADA A LA EDAD.

Investigador Principal: PATRICIA UDAONDO MIRETE

150998-005 . 2016

EFICACIA Y SEGURIDAD DEL BIMATOPROST DE LIBERACIÓN LENTA EN PACIENTES CON GLAUCOMA DE ÁNGULO ABIERTO O HIPERTENSIÓN OCULAR.

Investigador Principal: MERCEDES HURTADO SARRIÓ

192024-091 . 2015

EVALUACIÓN MULTICÉNTRICA POSCOMERCIALIZACIÓN DEL IMPLANTE AQUESYS XEN EN PACIENTES CON GLAUCOMA DE ÁNGULO ABIERTO PRIMARIO MODERADO.

Investigador Principal: JORGE VILA ARTEAGA

MS-001 . 2014

Cita

Compartir